The global life sciences industry is advancing rapidly. Increased generic competition, the changing patent landscape, evolving regulations, and pricing pressures present new challenges and opportunities for companies across the sector.
Our cross-disciplinary team can steer you through every phase of your life cycle, helping you carefully consider all of your options, and execute effective growth strategies—whether through licensing, M&A deals, or other types of transactions.
And while we have a lot of experience with transactions and litigation for large public companies, we have a passion for helping mid-market and startup companies grow.
The rapidly changing life sciences ecosystem presents a lot of exciting opportunities. We’re focused on helping clients leverage those opportunities and make strategic decisions that maximize their business potential.
Long Island Business News | January 11, 2017
Long Island office managing partner Allan Cohen provides an outlook on industries such as life sciences and biotechnology which have been areas of recent growth for Long Island.
Law360 | July 13, 2016
Boston Government Investigations & White Collar Defense partner Brian French, a member of the Life Sciences team, is quoted in this story looking at important cases the industry is monitoring for the remainder of the calendar year. Brian is quoted discussing False Claims Act matters.
Los Angeles Business Journal | June 22, 2015
This article focuses on a new $250 million independent fund created by the University of California to invest in research enterprises on its campuses. Los Angeles IP Counseling & Transactions partner Seth Levy talks about the research environment particularly for health care technologies and how it’s changed with regard to what it takes to get technology licensed or spun out.
Law360 | February 05, 2015
Washington, DC, Health Care and Life Sciences partner Areta Kupchyk is quoted in this article discussing the legacy of departing U.S. Food and Drug Administration Commissioner Margaret Hamburg.
Law360 | January 02, 2015
Boston IP Litigation and Life Sciences partner Maia Harris is quoted in this feature article on what to watch in life sciences in 2015.
Law360 | October 27, 2014
Boston IP Litigation partner Maia Harris, Boston Commercial Litigation partner Fred Kelly and Boston Government Investigations & White Collar Defense law clerk Charles Dell'Anno authored this article discussing the application of the U.S. Supreme Court’s decision in Pom Wonderful LLC v. The Coca-Cola Company to Lanham Act challenges related to drug labeling and marketing.
InformationWeek | October 06, 2014
Los Angeles Health Care partner Jill Gordon is featured in this article discussing big data’s role in health care. Jill’s comments are from her panel discussion at the 8th annual Body Computing Conference. Click here to read the full article.
Daily Journal | August 27, 2014
Los Angeles office managing partner Seth Levy and Los Angeles patent agent Stephen Chen co-authored this column looking at the state of stem cells and what’s next.
Law360 | August 13, 2014
Health Care and Life Sciences leader Michele Masucci is profiled in this Law360 Q&A series with dealmaking movers and shakers.
Law360 | July 28, 2014
Washington, DC, Health Care and Life Sciences partner Areta Kupchyk is quoted in this forward-looking feature story on new rules and guidance from the U.S. Food and Drug Administration making waves for drug and device makers.
Bloomberg BNA Health IT Law & Industry Report | July 21, 2014
Washington, DC, Health Care and Life Sciences partner Areta Kupchyk authored this article discussing a potential new Food and Drug Administration framework for mobile medical apps and health IT. Click here to read the full article.
Law360 | June 16, 2014
Boston Commercial Litigation partner Chris Allen and Boston Commercial Litigation associate Josh Barlow authored this column discussing the decision in Eckhardt v. Qualitest Pharmaceuticals Inc., which rejected theories of “innovator liability” asserted against manufacturers of branded drugs.
Mediuutiset (Finland) | March 21, 2014
In this Finnish health care publication, Boston Patents counsel Leena Karttunen Contarino provides commentary on how the FDA defines personalized medicine and about the FDA’s attempts to handle personalized medicine drugs and devices in an integrated process.
Intellectual Property Alert | 02.24.17
Health Care Alert | 01.19.17
Intellectual Property Alert | 03.25.16
Government Investigations & White Collar Defense Alert | 02.09.16
NP Privacy Partner | 01.22.16
FDA Alert | 01.05.16
FDA Alert | 01.04.16
FDA Alert | 12.28.15
10.07.15 | Los Angeles, CA
06.16.15 | Los Angeles, CA
05.06.14 | Jericho, NY